Oleuropein (Secoiridoid Glycoside · Blood Pressure · Antimicrobial)

Compound	Oleuropein
Chemical class	Secoiridoid Glycoside (Elenolic Acid + Hydroxytyrosol + Glucose Ester)
CAS	32619-42-4
Primary source	Olea europaea (olive leaf, unripe olive fruit)
Key applications	Antioxidant, antimicrobial, cardiovascular, anti-inflammatory
Claim strength	Moderate
Typical form	Olive leaf extract standardised to oleuropein (20% or 40%)
Buy from Herbuno	Oleuropein 40% Powder (Olive Leaf Extract) | Standardized Olea europaea → Oleuropein 20% Powder (Olive Leaf Extract) | Standardized Olea europaea →

Commercial source: Oleuropein is commercially available as a standardised olive leaf extract at 20% and 40% oleuropein content by HPLC, from Olea europaea leaf. See sourcing options below. Traditional use: Olive leaf preparations have been used in Mediterranean folk medicine for millennia for fever, hypertension, antimicrobial, and anti-inflammatory applications — the olive tree being one of the oldest cultivated plants in the world. Oleuropein is now identified as the primary secoiridoid glycoside responsible for olive leaf’s pharmacological activity, co-occurring with hydroxytyrosol (its hydrolysis product) and ligstroside. Research trajectory: Oleuropein has a substantial preclinical evidence base for antimicrobial (including antibacterial, antiviral, antifungal), cardiovascular, anti-inflammatory, and antioxidant mechanisms. Human clinical studies using olive leaf extract standardised to oleuropein content demonstrate blood pressure reduction, lipid improvement, and antioxidant effects. It has EFSA-related significance as the parent compound of hydroxytyrosol — the EFSA-approved olive polyphenol. See sourcing options below.

---

Evidence for Oleuropein Applications

Blood pressure reduction: Human RCTs with olive leaf extract standardised to oleuropein show clinically meaningful reductions in systolic blood pressure (5–10 mmHg) over 8–12 weeks in hypertensive patients. Mechanisms include ACE inhibition, calcium channel blocking activity, and eNOS-mediated vasodilation. A crossover RCT demonstrated equivalent blood pressure reduction to captopril (ACE inhibitor drug) at 500 mg olive leaf extract twice daily. Claim strength: Moderate.

Antimicrobial activity: Oleuropein and its aglycone (oleuropein aglycone, formed by gut hydrolysis) have potent broad-spectrum antimicrobial activity against bacteria (including MRSA, E. coli, Helicobacter pylori), viruses (influenza, HIV in vitro), and fungi (Candida albicans). The calcium chelation mechanism disrupts microbial metal-dependent enzyme activity. Claim strength: Moderate.

Cardiovascular and antioxidant: Oleuropein is a potent antioxidant via its phenolic hydroxyl groups and the EFSA-established LDL oxidation protection mechanism applies to olive polyphenols including oleuropein and hydroxytyrosol collectively. Lipid profile improvements (LDL reduction, HDL increase) documented in human supplementation studies. Claim strength: Moderate.

---

Dosage & Formulator Specification

Blood pressure clinical studies: 500 mg twice daily (1000 mg/day) of olive leaf extract standardised to 20% oleuropein (delivering 200 mg/day oleuropein). For antioxidant applications aligned with EFSA claim conditions (which reference hydroxytyrosol and derivatives including oleuropein), 5 mg/day hydroxytyrosol equivalent is the minimum — achievable with a much lower oleuropein dose (oleuropein is partially converted to hydroxytyrosol in vivo).

Specify oleuropein content by HPLC (20% or 40% grades available). The 40% grade from Herbuno provides a more concentrated active for reduced serving size in premium formulations. Note the relationship between oleuropein and hydroxytyrosol: 1 mol oleuropein yields 1 mol hydroxytyrosol on hydrolysis, so 100 mg oleuropein provides approximately 30 mg hydroxytyrosol equivalent — relevant to EFSA claim dose calculations.

Oleuropein is water-soluble (glucoside moiety). Stable at neutral to acidic pH. Gut hydrolysis by beta-glucosidases and esterases releases the aglycone and hydroxytyrosol. Standard supplement formats are appropriate. Bitter taste at concentrations above ~0.1% in liquid formats — relevant for RTD applications.

---

Frequently Asked Questions — Oleuropein

What is the difference between oleuropein and hydroxytyrosol in terms of formulation?
Oleuropein is the intact secoiridoid glycoside with elenolic acid and hydroxytyrosol components. It is more stable as an extract constituent and available at higher concentrations in olive leaf extract. Hydroxytyrosol is the simpler phenylethanol with superior bioavailability (~60–70% oral absorption) and CNS penetration. For EFSA claim purposes, both contribute to the olive polyphenol dose as “hydroxytyrosol and its derivatives.” For straightforward antioxidant LDL-protection positioning, olive leaf extract standardised to oleuropein is the more economical route to EFSA claim compliance.

Is olive leaf extract equivalent to extra virgin olive oil for cardiovascular benefit?
Olive leaf extract is much more concentrated in oleuropein than extra virgin olive oil — olive oil contains oleuropein primarily in unripe fruit (ripe oil has very little), whereas the leaves maintain high oleuropein throughout. Cardiovascular benefits from olive oil consumption in Mediterranean diet studies are attributed to oleic acid (fatty acid) and polyphenols collectively. Olive leaf extract provides a polyphenol-concentrated supplement format with clinical evidence specifically for blood pressure management not replicated by olive oil supplementation alone.

Can oleuropein be used for H. pylori eradication?
In vitro, oleuropein demonstrates potent H. pylori inhibition. Human clinical evidence for oleuropein specifically as an H. pylori eradicating agent is limited to pilot studies. Olive leaf extract cannot be recommended as a primary H. pylori treatment (which requires antibiotic triple therapy) but may have adjunctive supporting potential. Do not position as a H. pylori treatment claim.

Is oleuropein safe for long-term daily supplementation?
Olive leaf extract including oleuropein has a well-documented safety profile consistent with centuries of olive leaf consumption in Mediterranean populations and multiple controlled clinical trials without adverse effects at studied doses (500–1000 mg/day extract). The most commonly reported minor effects are GI discomfort at higher doses. Standard supplement advisory language applies; no specific safety concerns are documented at therapeutic doses.

---

Claim-strength scale – High = multiple human RCTs; Moderate = limited trials or strong preclinical convergence; Emerging = early-stage lab or animal data.

← HerbIQ Compound Index · HerbIQ P02: Extraction · HerbIQ P03: Delivery